Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

JOHN SATTERFIELD FORDTRAN

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1639386550
CMS profile
74635
Location
DALLAS, TX

General Payments · PY2018–2024

$11,098,350.14

  • Reported across 88 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$705,176.91

12 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Royalty or License $705,176.91 12

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Affordable Pharmaceuticals, LLC $481,019.91 4
Braintree Laboratories, Inc. $224,157.00 8

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $1,949,845.50 12
PY2019 $2,700,445.48 16
PY2020 $1,974,282.92 12
PY2021 $1,851,691.69 12
PY2022 $1,136,924.69 12
PY2023 $779,982.95 12
PY2024 $705,176.91 12

Payment records · PY2024 (12)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Affordable Pharmaceuticals, LLC $129,463.24 01/29/2024 Royalty or License Undisputed 01/23/2026 1125512543 CMS
Affordable Pharmaceuticals, LLC $146,064.15 04/25/2024 Royalty or License Undisputed 01/23/2026 1125512545 CMS
Affordable Pharmaceuticals, LLC $128,906.37 07/25/2024 Royalty or License Undisputed 01/23/2026 1125512547 CMS
Affordable Pharmaceuticals, LLC $76,586.15 10/24/2024 Royalty or License Undisputed 01/23/2026 1125512549 CMS
Braintree Laboratories, Inc. $525.74 01/29/2024 Royalty or License Undisputed 01/23/2026 1125514399 CMS
Braintree Laboratories, Inc. $64,118.49 01/29/2024 Royalty or License Undisputed 01/23/2026 1125514401 CMS
Braintree Laboratories, Inc. $267.07 04/25/2024 Royalty or License Undisputed 01/23/2026 1125514403 CMS
Braintree Laboratories, Inc. $54,167.04 04/25/2024 Royalty or License Undisputed 01/23/2026 1125514405 CMS
Braintree Laboratories, Inc. $48,929.02 07/25/2024 Royalty or License Undisputed 01/23/2026 1125514407 CMS
Braintree Laboratories, Inc. $620.57 07/25/2024 Royalty or License Undisputed 01/23/2026 1125514409 CMS
Braintree Laboratories, Inc. $52,478.56 10/24/2024 Royalty or License Undisputed 01/23/2026 1125514411 CMS
Braintree Laboratories, Inc. $3,050.51 10/24/2024 Royalty or License Undisputed 01/23/2026 1125514413 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.